Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of c...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2022-08-01
Schriftenreihe:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Schlagworte:	canagliflozin chronic kidney disease diabetes recurrent cardiovascular event
Online-Zugang:	https://www.ahajournals.org/doi/10.1161/JAHA.121.025045
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!